England’s MMR vaccinations up 23% following NHS initiative – Pharmaceutical Technology

Englands NHS is calling its recent campaign to boost vaccination rates a success amidst a surge in measles, mumps, and rubella (MMR) cases.

Latest data released by the health service shows that there were 23% more vaccinations in the first quarter of 2024 compared to the same time last year.

A total of 360,964 jabs were delivered between January and March this year, compared to 293,847 in 2023. The biggest jump was seen in those aged five to 25 years old, with vaccinations up four-fold in that group between 2024 and 2023.

In January, the UK Health Security Agency (UKHSA) declared a national incident following a surge in measles outbreaks across Britain. The highly contagious measles virus can cause serious illness and, in some cases, even death, in children and adults. It is also dangerous if caught during pregnancy, potentially resulting in stillbirth, miscarriage, and low birth weight.

In the same month, the NHS started contacting millions of patients and carers in England to book their children in for a catch-up vaccine with a GP. The campaign also targeted those in the 11 to 25 year-age group in areas with low vaccine uptake rates such as London and the West Midlands.

At the time, the NHS said its figures indicated that more than 3.4 million children under 16 years of age were unprotected against the three infectious diseases. There have been 934 confirmed cases of measles in England since the beginning of October last year, according to data from the UKSHA. The West Midlands accounted for around half of the cases seen since January.

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Your download email will arrive shortly

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

Country * UK USA Afghanistan land Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Cte d"Ivoire Croatia Cuba Curaao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Runion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo

Industry * Academia & Education Aerospace, Defense & Security Agriculture Asset Management Automotive Banking & Payments Chemicals Construction Consumer Foodservice Government, trade bodies and NGOs Health & Fitness Hospitals & Healthcare HR, Staffing & Recruitment Insurance Investment Banking Legal Services Management Consulting Marketing & Advertising Media & Publishing Medical Devices Mining Oil & Gas Packaging Pharmaceuticals Power & Utilities Private Equity Real Estate Retail Sport Technology Telecom Transportation & Logistics Travel, Tourism & Hospitality Venture Capital

Tick here to opt out of curated industry news, reports, and event updates from Pharmaceutical Technology.

Submit and download

UKSHA head of immunisation Dr Mary Ramsay said: The big increase in people, especially children, getting their MMR vaccine following our recent marketing campaign on missed immunisations is fantastic to see.

The NHS uses MSDs M-M-RVaxPro and GSKs Priorix for MMR vaccines. The shots were approved for use in the UK in 1997 and 2006, respectively. They are recommended for all babies and young children, with adults able to receive one if unvaccinated.

Two doses of the vaccines are required, resulting in lifelong protection with high efficacy against the three viruses which are easily spread between unvaccinated people.

The World Health Organization (WHO) has said 95% vaccine coverage would eliminate measles in a population completely.

The US has also seen a surge in measles cases, with the Centers for Disease Control and Prevention (CDC) reporting 97 cases in 2024 so far. Over half of the patients diagnosed with the virus were hospitalised. The CDC issued a health alert urging travellers, especially children, to get vaccinated. A statement from the American Medical Association echoed the call for vaccinations. The US also uses MSDs M-M-R II and GSKs Priorix.

Give your business an edge with our leading industry insights.

View original post here:

England's MMR vaccinations up 23% following NHS initiative - Pharmaceutical Technology